3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Other hematologic neoplasm
2
Myeloid
2
Gastrointestinal
2
Other solid neoplasm
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Interventions
Ipilimumab
101
pembrolizumab
94
Nivolumab
87
Cyclophosphamide
69
fludarabine phosphate
55
aldesleukin
52
Interleukin-2
39
Dacarbazine
35
Vemurafenib
31
fludarabine
30
trametinib
29
dabrafenib
29
Temozolomide
28
Whole-Body Irradiation
21
Aminolevulinic Acid
21
Carboplatin
20
CTLA-4 Antigen
20
Bevacizumab
20
Radiotherapy
19
Peripheral Blood Stem Cell Transplantation
19
Radiosurgery
18
Tacrolimus
17
Mycophenolic Acid
17
Paclitaxel
16
HhAntag691
16
3-ingenyl angelate
16
Busulfan
15
Introns
14
Antilymphocyte Serum
14
encorafenib
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
bemcentinib
×
Dermatologic
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts